



04/18/97

Express Mail No.: EM 178 494 108 US

PENNIE & EDMONDS LLP

COUNSELLORS AT LAW

1155 Avenue of the Americas

New York, N.Y. 10036-2711

(212) 790-9090

60854 U.S. PTO

08/18/97



04/18/97

ATTORNEY DOCKET NO. 8678-004-999

Date April 18, 1997

Assistant Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): PAMELA A. CONTAG, DAVID A. BENARON, Executed on: UNEXECUTED
CHRISTOPHER R. CONTAG

Title of Invention: BIODETECTORS TARGETED TO SPECIFIC LIGANDS

Pages of Specification 38

Sheets of Drawings 5

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	20	-20	0	\$22.00 each	0.00
Independent	2	-3	0	\$80.00 each	0.00
Minimum Fee					770.00
Multiple Dependency Fee If Applicable (\$260.00)					
Total					770.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern (a verified statement as to the applicant's status is attached)					- 385.00
Total Filing Fee					\$ 385.00

Priority of application no. 60/015,633 filed on APRIL 19, 1996 in BIODETECTORS TARGETED TO SPECIFIC LIGANDS is claimed under 35 U.S.C. § 119.

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Albert P. Halluin

Albert P. Halluin
PENNIE & EDMONDS LLP

25,227

(Reg. No.)

Enclosure

This form is not for use with re-issue, design or plant patent applications.

by James E. Smith 29,258

385-201 A



APPLICATION
IN THE UNITED STATES PATENT OFFICE

ENTITLED:

BIODETECTORS TARGETED TO SPECIFIC LIGANDS

Inventors:

Pamela R. Contag
David A. Benaron
Christopher H. Contag

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
Tel: (212) 790-9090
Attorney Docket No.: 8678-004-999

BIODETECTORS TARGETED TO SPECIFIC LIGANDS

TABLE OF CONTENTS

		<u>Page</u>
5		
I.	FIELD OF THE INVENTION	- 1 -
II.	BACKGROUND OF THE INVENTION	- 1 -
10 III.	SUMMARY OF THE INVENTION	- 6 -
IV.	BRIEF DESCRIPTION OF THE FIGURES	- 7 -
V.	DEFINITIONS	- 7 -
VI.	DETAILED DESCRIPTION OF THE INVENTION	- 8 -
15		
A.	General Overview Of The Invention	- 8 -
B.	Biodetectors	- 9 -
	1. Entities Sheltering Biodetectors	- 13 -
20		
	2. The Signal-Converting Element	- 14 -
	3. Transducers	- 16 -
	4. Reporter Genes And Operons	- 16 -
25	C. Imaging Of Light-Emitting Biodetectors	- 19 -
	1. Photodetector Devices	- 19 -
	2. Constructing An Image Of Photon Emission	- 21 -
30	D. Applications	- 22 -
VII.	EXAMPLES	- 25 -
	A. Example 1: Linking Signal Transduction To The Regulation Of A Specific Genes (Approach 1)	- 25 -
35		
	B. Example 2: Linking Signal Transduction To The Regulation Of A Specific Genes (Approach 2)	- 26 -

	<u>Page</u>
C. Example 3: Linking Signal Transduction To The Regulation Of A Specific Genes (Approach 3)	- 27 -
D. Example 4: Detection Of Substances in Solution	- 28 -
5 E. Example 5: Detection of Substances On Solid Support	- 28 -
F. Example 6: Effect Of Human Blood On The Light Emission From Bioluminescent <i>Salmonella</i>	- 28 -
IT IS CLAIMED:	- 30 -
10 ABSTRACT	- 33 -

15

20

25

30

35

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BIODETECTORS TARGETED TO SPECIFIC LIGANDS

5

This application claims the benefit of U.S. Provisional Application Number 60/015,633, filed April 19, 1996.

I. FIELD OF THE INVENTION

10

The present invention relates to biodetectors for detecting and quantifying molecules in liquid, gas, or on solid matrices. More specifically, the present invention relates to biodetectors comprising a molecular switching mechanism to express a reporter gene upon interaction with target substances. The invention further relates to
15 methods using such biodetectors for detecting and quantifying selected substances with high specificity and high sensitivity.

II. BACKGROUND OF THE INVENTION

20

The detection of low-levels of biological and inorganic materials in biological samples, in the body or the environment is frequently difficult. Assays for this type of detection involve multiple steps which can include binding of a primary antibody, several wash steps, binding of a second antibody, additional wash steps, and depending on the detection system, additional enzymatic and washing steps. Such assays further
25 suffer from lack of sensitivity and are subject to inaccuracies. For instance, traditional immunoassays miss detecting 30% of infections.

Molecular probe assays, although sensitive, require highly skilled personnel and knowledge of the nucleic acid sequence of the organism. Both the use of nucleic acid
30 probes and assays based on the polymerase chain reaction (PCR) can only detect nucleic acid which require complicated extraction procedures and may or may not be the primary indicator of a disease state or contaminant. Both types of assay formats are limited in their repertoire in cases where little information is available for the entity to
35 be detected.

Current noninvasive means to measure a patients physical parameters such as CAT or MRI, are expensive and are often inaccessible. Thus, the monitoring of many

medical problems still requires tests, which can be slow and expensive. The time between the actual test and the confirmation of the condition may be very important. For example, in the case of sepsis, many patients succumb before infection is confirmed and the infecting organism identified, thus treatment tends to be empirical and less effective. Another example is in screening the blood supply for pathogens.

Verification of a pathogen free blood supply requires a number of labor intensive assays. In the case of HIV-1, the virus that causes AIDS, the current assays screen for anti-HIV antibodies and not the virus itself. There is a window lasting up to many weeks after exposure to the virus in which antibodies are not detectable, and yet the blood contains large amounts of infectious virus particles. Clark *et al.*, 1994, *J. Infect. Dis.* 170:194-197; Piatak *et al.*, 1993, *Aids Suppl.* 2:S65-71.

For example, in order to verify that a blood supply is free of HIV-1, several labor-intensive, expensive tests must be performed. Moreover, tests currently in use for initial screening do not identify the virus itself, which can be present at relatively low levels, but are directed to HIV antibodies which are not present for weeks after an initial infection. Clark *et al.*, 1994, *J. Infect. Dis.* 170:194-197; Piatak *et al.*, 1993, *Aids Suppl.* 2:S65-71. Thus, screening of the blood supply is not only time-consuming and slow, it may also be inaccurate.

Similarly, the ability to detect substances in the environment, such as airborne and waterborne contaminants is of great importance. For example, it would be desirable to monitor groundwater, to control industrial processes, food processing and handling in real-time using an inexpensive versatile assay. However, current methods are not suited for such "on-line" monitoring.

There are several reasons why current methods are limited. First, access to sufficient amounts of the material to be detected may be difficult. For example, the detection of biological materials can be difficult as the biological materials of interest are often sequestered inside a body, and large quantities can be difficult to obtain for *ex vivo* monitoring. Therefore, sensitive assays for use on small amounts of material are necessary. This indicates that a method of amplifying the signal is required. Amplification methods have been established for detection of nucleic acid but this is not the case for antigen detection methods.

A second problem is that sensing may be difficult in real-time because the target materials may be present in small quantities that detection of their presence requires time-consuming, expensive and technical by-involved processes. For example, in the case of bacterial infections in the blood, sepsis, there may be only 1-2 bacteria in a 1-10 ml blood sample. Current methods require that the bacteria are grown first in order to be detected. Askin, 1995, *J. Obstet. Gynecol. Neonatal. Nurs.* 24:635-643.

This time-lag may be detrimental as delaying treatment or mistreating diseases may mean the difference between life and death.

Others have attempted to avoid these limitations by using radioactive or fluorescent tags in combination with antibodies (Harlow *et al.*, (1988), Antibodies. A Laboratory Manual (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). Antibody-based assays typically involve binding of an antibody to the target molecule, followed by a series of washing steps to remove all unbound antibodies. Binding of the antibody to its target molecule is typically detected by an identifier molecule, for example a secondary antibody specifically recognizing the target molecule specific antibody which contains a detectable label. The step is also followed by multiple wash steps. Alternatively, the target-specific antibody may directly be attached to a detectable label. Labels have included radioactive tracers, fluorescent tags, and chemiluminescent detection systems. Harlow and Lane, 1988, Antibodies. A Laboratory Manual (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press).

The series of steps required using such antibody-based assays to generate a specific signal are time consuming and labor intensive. Furthermore, these type of assays are limited to the detection of antigens fixed to some type of matrix. Examples of this type of detection system include Western blots, immunohistochemistry, and ELISA. The highest sensitivity is currently being achieved using radioisotopic and chemiluminescent tags. However, sensitivity, *i.e.*, specific signal over background, of these detection systems frequently remains a limiting factor.

Similarly, background radiation places limits on the sensitivity of radioactive immunoassay techniques. In addition, these techniques are time-consuming and expensive. Finally, radioactive approaches are hostile to the environment, as they present significant waste disposal problems.

Another approach to monitoring substances involves the use of light. Light has the advantage that it is easily measurable, noninvasive and quantitative. Von Bally *et al.*, (1982), Optics in Biomedical Sciences: Proceedings of the International

5 Conference (Berlin, New York: Springer-Verlag).

Traditional spectroscopy involves shining light into substances and calculating concentration based upon the absorbance or scattering of light. Von Bally *et al.*, (1982), Optics in Biomedical Sciences: Proceedings of the International Conference (Berlin, New York: Springer-Verlag). Optical techniques detect variations in the
10 concentration of light-absorbing or light scattering materials. Von Bally *et al.*, (1982), Optics in Biomedical Sciences: Proceedings of the International Conference (Berlin, New York: Springer-Verlag). Near-infrared spectroscopy has proved to be a nonionizing, relatively safe form of radiation that functions well as a medical probe as it
15 can penetrate into tissues. Further, it is well-tolerated in even large dosages. For example, light is now used to calculate the concentration of oxygen in the blood (Nellcor) or body (Benaron image), or even to monitor glucose in the body (Sandia). Benaron and Stevenson, 1993, *Science* 259:1463-1466; Benaron *et al.*, 1993, in:
20 Medical Optical Tomography: Functional Imaging and Monitoring, G. Muller, B. Chance, R. Alfano and e. al., eds. (Bellingham, WA USA: SPIE Press), pp. 3-9; Benaron and Stevenson, 1994, *Adv. Exp. Med. Biol.* 361:609-617. However, current techniques are limited in that many substances do not have unique spectroscopic
25 signals which can be optically assessed easily and quantitatively. Von Bally *et al.*, (1982), Optics in Biomedical Sciences: Proceedings of the International Conference (Berlin, New York: Springer-Verlag). Furthermore, the detection of substances at low concentration is frequently hampered by high background signals, especially in biological media such as tissues. Von Bally *et al.*, (1982), Optics in Biomedical
30 Sciences: Proceedings of the International Conference (Berlin, New York: Springer-Verlag).

Over the past years, assays based on light emission, for example chemiluminescence (Tatsu and Yoshikawa, 1990, *Anal. Chem.* 62:2103-2106), have
35 attracted increasing attention due to the development of extremely sensitive methods for detecting and quantifying light. Hooper *et al.*, 1994, *J. Biolumin.*

Chemilumin. 9:113-122. One example of a biomedical research product using chemiluminescence is the ECL detection system (Amersham) for immunoassays and nucleic acid detection.

5 The use of biological sources of light, bioluminescence, for biological assays has paralleled development of chemiluminescent detection, as similar devices for light detection are required. Kricka, 1991, *Clin. Chem.* 37:1472-1481. One of the most commonly employed biological source of light is luciferase, a light-generating enzyme synthesized by a range of organisms, including *Photinus pyralis* (American
10 firefly), *Renilla reniformis* (phosphorescent coral), and *Photobacterium* (Luminescent bacterial species). Generally, luciferase is a low molecular weight oxidoreductase, which catalyzes the dehydrogenation of luciferin in the presence of oxygen, ATP and magnesium ions. During this process, about 96% of the energy
15 released appears as visible light. For review, see, Jassim *et al.*, 1990, *J. Biolumin. Chemilumin.* 5:115-122.

The sensitivity of photon detection and the ability to engineer bacteria and other cells to express bioluminescent proteins permit the use of such cells as sensitive
20 biosensors in environmental studies. Guzzo *et al.*, 1992, *Toxicol. Lett.* 64:687-693; Heitzer *et al.*, 1994, *Appl. Environ. Microbiol.* 60:1487-1494; Karube and Nakanishi, 1994, *Curr. Opin. Biotechnol.* 5:54-59; Phadke, 1992, *Biosystems* 27:203-206; Selifonova *et al.*, 1993, *Appl. Environ. Microbiol.* 59:3083-3090. For example, Selifonova *et al.* describe biosensors for the detection
25 of pollutants in the environment. More specifically, using fusions of the *Hg(II)* inducible Tn21 operon with the promoterless *luxCDABE* from *Vibrio fischeri*, highly sensitive biosensors for the detection of *Hg(II)* have been constructed.

In addition to systems where bioluminescence is used as detection method of a
30 specific condition, *e.g.*, the presence of *Hg(II)*, *supra*, constitutive expression of luciferase has been employed as marker to track viability of bacterial cells, as the luciferase assay is dependent on cell viability. For example, constitutive expression of luciferase has recently been employed for the development of drugs and vaccines
35 directed against bacterial disease. Specifically, using an enhanced luciferase-expressing *Mycobacterium tuberculosis* strain has been employed to evaluate

antimicrobial activity in mice. Hickey *et al.*, 1996, *Antibacterial Agents and Chemotherapy* 40:400-407.

However, biosensors that rely on a bacterial receptor to turn on a luciferase are limited to sensing those molecules that have a corresponding bacterial receptor, linked to a known promoter region which can be fused to the luciferase gene. Further, the luciferase-expressing bacteria used to test antimicrobial activity in mice are nonspecific.

Thus, while methods have been explored using the bioluminescence in general, and luciferase in particular, as bioluminescent sensors for very specific applications, the present invention is directed to highly sensitive and highly selective ligand-specific biotectors for a very broad range of applications. More specifically, the present invention combines the selectivity of ligand-specific binding and the versatility of the antibody repertoire with the sensitivity of bioluminescent detection, employing entities that specifically respond with photon emission to predetermined ligands. The approach of the present invention thus permits the generation of extremely sensitive biotectors for the development of a wide variety of assays detecting any number of commercially important molecules.

III. SUMMARY OF THE INVENTION

The present invention is directed to targeted ligand-specific biotectors for detecting and monitoring selected substances. More specifically, the biotectors of the present invention comprise (1) a signal converting element, comprising an extracellular ligand-specific binding moiety, which is fused to an intracellular signal transforming domain which is capable of activating a (2) transducer component, which in its active form is capable of activating a (3) responsive element, such as a promoter which is operatively linked to a (4) reporter gene, encoding for a polypeptide with unique properties that are easily detected, for example optically. Thus, the biotectors of the invention convert the binding to a target substance, *i.e.*, a ligand, into a detectable signal. In preferred embodiments of the invention, the signal generated by the biotector is light and is detected by a light-detecting device. Accordingly, a substance of interest may be identified.

The present invention is further directed to methods using such biodetectors for detecting and monitoring selected substances at high sensitivity and high specificity. The methods using the biodetectors of the invention include the detection of contaminants in the food and agriculture industry, diagnosis and monitoring in medicine and research, and detection of poisons or contaminants in the environmental or defense setting.

IV. BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1 depicts a generic model demonstrating the main components of a biodetector. A biodetector consisting of an entity possessing sensing ("Y-shaped structure on surface), transducing components (part of "Y-shaped" structure inside of biodetector) and light-emitting components (small circles).

FIGURE 2 depicts a more specific scheme of a biodetector on the molecular level.

FIGURE 3 depicts an ordered array of biodetectors on a solid support such that a variety of substances in a sample can be detected simultaneously.

FIGURE 4 depicts a biodetector generated by the integration of a transposon in the bacterial genome as specified in EXAMPLE 1. The luciferase operon encodes five proteins (from genes A, B, C, D and E) that together can produce bioluminescence. Chl, chloramphenicol resistance gene; Kan, kanamycin resistance gene; Amp, Ampicillin resistance gene; PO₄, phosphate group (as activator of the transducer).

FIGURE 5 depicts the effect of human blood on the light emission from bioluminescent *Salmonella*, demonstrating near single cell detection.

V. DEFINITIONS

Unless otherwise indicated, all terms used herein have the same meaning as they would be understood by one skilled in the art.

The term "*target molecule*" as used herein describes a substance that is to be detected and/or quantified.

The term "*luciferases*" as used herein, unless otherwise stated, includes prokaryotic and eukaryotic luciferases as well as variants with varied or altered physical

and/or emission properties.

The term "*biodetector*" as used herein refers to an entity that responds with an optical signal to the binding or otherwise interacting with the target molecule.

5 The term "*optical signal*" as used herein refers to any biochemical reaction or substance that can be distinguished using light monitoring techniques. This includes photon emission, fluorescence, and absorbance.

10 The term "*light*" as used herein, unless otherwise stated, refers to electromagnetic radiation having a wavelength between about 220 nm and about 1100 nm.

The term "*promoter induction*" as used herein refers to an event that results in direct or indirect activation of a selected inducible genetic element.

15 VI. DETAILED DESCRIPTION OF THE INVENTION

A. General Overview Of The Invention

The present invention is directed to targeted ligand-specific biodetectors for detecting and monitoring selected substances, including microorganisms, molecules, and ions, for a wide range of applications. The biodetectors of the present invention combine the specificity and selectivity of ligand-specific binding with the sensitivity of bioluminescent detection by employing entities that specifically respond to the binding of a predetermined ligand with photon emission. Thus, the approach of the present invention permits the generation of sensitive biodetectors for the development of a wide variety of assays detecting and monitoring any selected substance.

25 More specifically, the biodetectors of the present invention provide for the coupling of ligand-specific binding, via a "molecular switch", *i.e.*, a signal transduction, with the activation of a detectable reporter molecule in response to ligand binding. The biodetectors of the present invention may consist of viable biological entities, such as bacteria, or abiotic entities, such as liposomes. As general scheme, the biodetectors are characterized by their ability to specifically recognize a ligand and convert binding to the ligand to a measurable signal, such as light emission. For example, bacteria may be employed as ligand-specific biodetectors, which specifically respond with photon emission to predetermined ligands.

The biodetectors of the present invention permit highly sensitive detection of a wide variety of substances, for example microbes in human blood, viruses and bacteria, toxic molecules, ions, cancer cells, antigens, small molecules (*e.g.*, glucose), pH, oxygen, and metals. Further, the present invention provides for the use of such
5 biodetectors in a wide variety of assays to detect any selected substance.

Generally, the biodetectors of the present invention comprise a signal converting element, comprising an extracellular ligand-specific binding moiety, which is coupled to an intracellular signal transforming domain which is capable of activating a transducer
10 component. The transducer component in its active form is capable of activating a responsive element, such as a promoter which is operatively linked to a reporter gene, encoding for a diagnostic polypeptide with unique properties that are readily detectable. In the alternative, a reporter molecule is activated directly by binding other intracellular
15 signal transforming domain of the signal converting element. Thus, the biodetectors of the invention convert the binding to a target substance, *i.e.*, a ligand, into a detectable signal. In preferred embodiments of the invention, the signal generated by the biodetector is light and is detected by a light-detecting device. Accordingly, based upon
20 this interaction, the targeted ligand(s) may be quantified and identified.

B. Biodetectors

The biodetectors of the invention are characterized in that they generate a detectable signal in response to either the presence of a targeted substance *in vivo* or
25 *in vitro*.

In one specific embodiment, light is the detectable signal generated by the biodetector in response to the presence of the targeted substance. As there is virtually no background light coming from normal tissues and other organic or inorganic
30 materials, the sensitivity of the system is limited only by the background noise of the biodetector. More specifically, the targeted ligand-specific biodetectors of the present invention consist of a ligand-specific domain, which, via a "molecular switch", is linked to a reporter gene encoding a detectable protein. The reporter gene is thus activated in
35 response to binding of the ligand to the ligand-specific domain. The ligand-specific binding moiety may be any antibody which selectively binds to the substance of interest.

The "molecular switch" is a signal transducing component which couples ligand binding to the activation of a responsive element. The transducing molecule can be any two component regulatory system of bacteria, including phosphate regulon, or any eukaryotic transducer. The responsive element may be an inducible promoter, operatively linked to a reporter gene. Transcription and translation of this reporter gene will result in a gene product which produces a detectable signal, such as light. The signal is detected by suitable means; in the case the signal is light, this means will be a photodetection device.

For example, imaging of the light-emitting biodetector entities may involve the use of a photodetector capable of detecting extremely low levels of light - typically single photon events. If necessary, localization of signal could be determined by integrating photon emission until an image can be constructed. Examples of such sensitive photodetectors include devices (such as microchannelplate intensifiers and photomultiplier tubes) that intensify the single photon events. Intensifiers may be placed before a camera. In addition, sensitive cameras (cooled, for example, with liquid nitrogen) that are capable of detecting single photons over the background noise inherent in a detection system may also be used.

Once a photon emission image is generated, it is typically superimposed on a "normal" reflected light image of the subject to provide a frame of reference for the source of the emitted photons. Such a "composite" image is then analyzed to determine the location and/or amount of a target in the subject. In most circumstances images of the light source are not required. Simple quantitation of the numbers of photons emitted from a sample (as detected for example by a luminometer) indicate the concentration of the light emitting reporter. The number of photons would therefore be proportional to the amount of targeted-ligand that a specific detector is sensing. Without the constraints imposed by the need for an image, detectors can be placed in very close proximity to the light-emitting biodetector thus optimizing the optical detection and sensitivity of the assay. Microchannel plate intensifiers can be used in such a configuration resulting in single photon detection. Such a device is currently manufactured by Hamamatsu Corporation. In the Hamamatsu system ATP concentrations from single cells can be assayed by spraying lysis buffer, luciferase and the substrate, luciferin, on immobilized

cells.

The generic mechanism of a ligand-specific biodetector is shown in FIGURE 1. FIGURE 2 shows the molecular mechanism of a preferred biodetector more specifically. In the depicted example, the biodetector is a bacterial cell expressing a transmembrane target specific signal converting element, comprising an extracellular ligand-specific binding moiety, *e.g.*, an antibody, which is coupled to an intracellular signal transforming domain. The target specific signal converting element is integrated in a membrane, *e.g.*, a bacterial membrane, which separates an "extracellular" compartment from an "intracellular" compartment. The ligand-specific moiety is capable of binding to a selected substance, which triggers the activation of the intracellular signal transforming domain. The activated intracellular signal transforming domain in turn converts an inactive transducer into an active transducer. The transducer is characterized by its capability to bind, when converted to its active form, to a promoter element, which is operatively linked to a reporter gene. Transcription and translation of the reporter gene or operon results in a gene product which produces a detectable signal, such as light. In preferred embodiments of the invention, the reporter is a luciferase operon, which produces visible light and can easily be monitored, measured and quantified with high sensitivity.

Alternatively, the signal transforming domain could act directly on a modified reporter molecule. The reporter molecule would be modified to be expressed in an inactive state which can then be activated through its interaction with the signal transforming domain directly.

The biodetectors, providing a "light switch" that responds to a predetermined selected substance presents a number of advantages over current methodologies. First, the switch allows for detection of antigens, present in complex mixtures and eliminates the need to wash off unbound antibodies, thus simplifying the detection. Since ligand bound to antibody turns on light and since there is no background light in the sample, no washing is necessary to reduce signal to noise ratio, reduced noise increases sensitivity, and only specific interaction turns on the light.

Once bound to a ligand, an enzymatic cascade is activated that serves to transmit the signal.

Moreover, if the targeted ligand is abundantly expressed on the surface of, for example, pathogenic microbes, many biodetecting bacteria will bind to a single target, thus serving to amplify the signal and result in extremely sensitive detection systems.

5 Furthermore, as the ligand-specific domain of the signal converting element of the biodetector system may be exchanged like a cassette, an unlimited number of biodetectors can be generated to recognize any desired or selected substance. Thus, the biodetectors of the present invention provide a flexible, generic system that be can adapted to recognize any selected substance, out of a wide variety of choices.

10 Biodetectors targeting a substance of interest can rapidly be developed.

The biodetectors of the invention are versatile as they are effective *in vivo*, in solution, or on fixed sensor plates. Furthermore, arrays of these biodetectors may be constructed, operating at different wavelengths or on different positions of a "biosensor

15 chip", allowing for simultaneous monitoring and screening of multiple agents, genes, gene products, or other targets. *See*, FIGURE 3. For example, the biodetectors may be assembled in a unique multi-detector array configuration for the purpose of constructing a system capable of a broad ranging, powerful analysis in a single step.

20 For example, the biodetector may be placed on a gel that lies on top of a normal signal detecting instrument, which, in the case the generated signal is light, may be, *e.g.*, a charge coupled device (CCD) chip. Due to the spatial recognition of signals by the CCD array, the biodetector array may provide for a light-based analysis using multiple different sensors placed in an array on one sensor chip. Thus, an analysis may be

25 simultaneously performed for, *e.g.*, blood type, HIV exposure, Hepatitis status, Lymphokine profiles and CMV positivity. Multiple types of infection to be rapidly and simultaneously screened.

If light is the signal produced by the reporter, the signal may be detected non-

30 invasively, as light can be detected through, for example, tissue. *See*, co-pending U.S. Patent Application No. 08/270,631, hereby incorporated by reference in its entirety.

Furthermore, as the biodetectors of the invention are biocompatible, and as such environmentally friendly, they have comparatively low developmental costs and a lower

35 burden to the user, especially when compared with methods that may involve toxic waste, such as radioactivity-based assays.

A further significant advantage of the biodetectors of the invention is the reduction in time and labor needed to perform many diagnostics tests. A common, rate-limiting step in many testing and diagnostic fields is the need for an accurate sensing and detection system suitable for providing immediate information. Examples include screening of the blood supply for the AIDS virus and other blood borne pathogens, the study and evaluation of novel drugs in tissue culture or animal models, and the monitoring of therapeutic protein output after genetic therapy. For example, the mandatory screening of the blood supply for HIV and other agents currently requires numerous tests. An inexpensive, rapid, and specific sensor detecting numerous blood borne pathogens with built-in confirmatory tests could significantly streamline the process, thus reducing net cost to the user. Similarly, the evaluation of potential new drugs, known as lead compounds, by pharmaceutical companies now requires elaborate, expensive tissue culture and animal trials. An inexpensive sensor and related hardware to allow *in vitro* and *in vivo* monitoring of drug kinetics and effectiveness will have great value to drug companies searching for ways to streamline such lead compound development.

In sum, the biodetectors of the invention provide numerous advantages over currently available diagnostic detection systems.

1. Entities Sheltering Biodetectors

The biological components of the biodetector may be contained in or otherwise may be attached to living or nonliving entities that stabilize the essential interactions. Configuration of these components as such results in a micro sensing system capable of detecting small numbers of ligands with great specificity and sensitivity.

Living Entities. Most typically, the biodetector entity is a living cell which is genetically engineered to comprise all required components. Living entities include, but are not limited to, prokaryotes, eukaryotes, viruses, retroviruses, vectors, plasmids, phage, transformed eukaryotic cells, such as lymphocytes, macrophages, established cell lines. Most typically, the entity sheltering a genetically engineered bacterial cell, as *E. coli*. Genetically-modified bacteria can be grown rapidly at low cost, thus the

advantage of the use of living cells as biodeceptor entity is that pools of these biodeceptors can be replicated and grown once the original biodeceptor is constructed.

The use of "living" biodeceptor entities has several advantages. First, it allows the growth of biodeceptors at low cost, once the sensors are engineered. Second, it allows a system wherein a detector can grow and continue to develop within a tissue, rather than wearing out as would a conventional inorganic sensor. Third, a living biodeceptor can amplify the detected signal. For example, the binding of one antigen to the surface of the bacteria can trigger a series of light-generating substances to be made, each of which can produce light in a repetitive manner. Thus, the binding of one antigen that properly stimulates the system can result in the production of large amounts of photons from one living biosensor. Forth, as these biosensors may bind in large numbers to a target, the result is that many biodeceptors, *i.e.*, bacteria, with each amplifying the binding event, leading to a high degree of amplification. Thus, extremely high sensitivity can be achieved.

Non-Living Entities. However, abiotic biodeceptors may be generated as well. The biodeceptor system may be placed in an inanimate gel, in abiotic capsules and liposomes and as such be injected into the body, or mounted on plates. Further, any other entity capable of preserving vectorial metabolism such as a lipid bilayer may be employed.

2. The Signal-Converting Element

The signal converting element is composed of an "extracellular" portion selectively binding a specific substance and an "intracellular" portion capable of activating the transducer. Typically, the signal converting element will be a transmembrane fusion protein composed of an extracellular ligand-binding portion, *e.g.* an antibody and an intracellular enzymatic portion, which is activated upon binding of the extracellular portion to a the selected target. Accordingly, the signal converting element is designed to convert the recognizing and binding of a specific substance, *i.e.*, ligand and into a intracellular signal, resulting in the activation of the transducer component, which in turn, activates a promoter that drives the expression of the reporter protein.

The Ligand-Binding Domain. Substances which may be identified by the present invention include, but are not limited to, proteins, peptides, sugars, fatty acids, ions, microorganisms, including bacteria, viruses and retroviruses. Accordingly, the ligand-binding domain may be an antibody, an antibody fragment, cellular receptor or any other ligand binding protein, such as Staphylococcus Proteins A and G, a macrophage Fc receptor, a carbohydrate moiety, or an ion-binding moiety, such as domains from sodium or potassium channels.

In specific embodiments, the ligand-binding domain is an antibody or a derivative thereof, including but not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. In particular the monoclonal antibody technology and the more recent development of techniques for expressing functional antibodies in bacterial cells have increased the versatility and ease of identifying suitable ligand-binding domains for any desired target. For details about the expression of antibodies in bacterial cells, *see*, among other places, Collet *et al.*, 1992, *Proc. Natl. Acad. Sci. U.S.A.* 89:10026-10030, and Huse *et al.*, 1989, *Science* 246:1275-1281.

Moreover, the source of the antibody coding regions is not limited to those cloned from hybridoma cell lines where the specificity of the antibody is known and is monoclonal in nature. Rather, large antibody libraries may be employed to generate the fusion proteins such that a large number of biodetectors for the detection of an indefinite range of antigens can be generated.

The Signal Transforming Domain. The signal transforming domain may consist of an enzyme or active domain of an enzyme that has any number of protein modifying functions which may include phosphorylation, dephosphorylation, methylation, acetylation and protease activity. Such enzymes include protein kinases, phosphorylases, protein methylases, acetylases, proteases, proteinase K, serine proteases among others. In a specific embodiment of this patent the active domain of the bacterial phosphorylase, PhoQ, will be fused in a gene fusion to a region of a heavy chain antibody cDNA. As such, interaction of the expressed fusion protein with the targeted

antigen (ligand) will result in a conformational change in the antibody-phosphorylase fusion that will activate the specific phosphorylase activity which activates PhoP, a transducer protein, through a phosphorylation/dephosphorylation event. Active PhoP
 5 activates the Pho promoter which is used to drive expression of the reporter operon lux. The transducer activating domain of the signal converting element is characterized in that it changes conformation or electronic charge upon binding a specific molecule, which results in activation of the transducer. The transducer may be activated by phosphorylation, glycosylation, methylation electron transport, hydrogen transport,
 10 carboxylation, dehydrogenation, oxidation/reduction or any other chemical modification.

3. Transducers

The transducer is activated by the signal converting element upon
 15 ligand binding. The transducer may be any molecule that can recognize and respond to a change in conformation, electrical charge, addition or subtraction of any chemical subgroup, such as phosphorylation, glycosylation, and in turn is capable of triggering a detectable response.

20 In specific embodiments of the invention, activation of the transducer triggers, directly or indirectly, the activation of a transcription activating element, *e.g.*, a promoter, to effect the activation of a reporter gene or reporter operon. Transcription and translation of the reporter gene or operon in turn results in a gene product or gene products which produces a detectable signal, such as light. However, in alternative
 25 embodiments, activation of the transducer may directly result in a visible and measurable signal.

4. Reporter Genes And Operons

30 A wide range of reporter genes or reporter operons may be employed, including such which result in bioluminescence, colorimetric reactions or fluorescence. For example, reporter genes may encode for pigments (Bonhoeffer, 1995, *Arzneimittelforschung* 45:351-356) such as bacterial rhodopsin (Ng *et al.*,
 35 1995, *Biochemistry* 34:879-890), melanin (Vitkin *et al.*, 1994, *Photochemistry and Photobiology* 59:455-462), aquorins (Molecular Probes,

Seattle), green fluorescent protein (GFP, Clontech, Palo Alto; Chalfie *et al.*, 1994, *Science* 263:802-805; Cubitt *et al.*, 1995, *TIBS* 20:448-455), yellow fluorescent protein (Daubner *et al.*, 1987, *Proc. Natl. Acad. Sci. U.S.A.* 84:8912-8916), flavins, bioflavinoids, hemoglobin (Chance *et al.*, 1995, *Analytical Biochemistry* 227:351-362; Shen *et al.*, 1993, *Proc. Natl. Acad. Sci. U.S.A.* 90:8108-8112), heme (Pieulle *et al.*, 1996, *Biochem. Biophys. Acta* 1273: 51-61), indigo dye (Murdock *et al.*, 1993, *Biotechnology* 11:381-386), peridinin-chlorophyll-a protein (PCP) (Ogata *et al.*, 1994, *FEBS Letters*, 356:367-371), or pyocyanine (al-Shibib and Kandela, 1993, *Acta Microbiologica Polonica* 42:275-280). Alternatively, reporter genes may encode for enzymes that can cleave a color absorbing substrate such as β -lactamase, luminescent and fluorescent proteins, enzymes with fluorescent substrates, or any other gene that encodes an optically active chemical or that can convert substrate to an optically active compound. In a further alternative, reporter genes may encode photoproteins, In each case, the reporter is operatively linked to an inducible promoter which is activated by the active form of the transducer component.

In a specific embodiment of the invention, bioluminescent reporters are employed.

Bioluminescence-Based Reporter Genes And Operons. Several types of bioluminescent reporter genes are known, including the luciferase family (*e.g.*, Wood *et al.*, 1989, *Science* 244:700-702). Members of the luciferase family have been identified in a variety of prokaryotic and eukaryotic organisms. Luciferase and other enzymes involved in the prokaryotic luminescent (*lux*) systems, as well as the corresponding *lux* genes, have been isolated from marine bacteria in the *Vibrio* and *Photobacterium* genera and from terrestrial bacteria in the *Xenorhabdus* genus, also called photorhalodus.

An exemplary eukaryotic organism containing a luciferase system (*luc*) is the North American firefly *Photinus pyralis*. Firefly luciferase has been extensively studied, and is widely used in ATP assays. cDNAs encoding luciferases from *Pyrophorus plagiophthalmus*, another species, click beetle, have been cloned and expressed (Wood *et al.*, 1989, *Science* 244:700-702). This beetle is unusual in

that different members of the species emit bioluminescence of different colors. Four classes of clones, having 95-99% homology with each other, were isolated. They emit light at 546 nm (green), 560 nm (yellow-green), 578 nm (yellow) and 593 nm (orange).

5 Luciferases requires a source of energy, such as ATP, NAD(P)H, and the like, and a substrate, such as luciferin, decanal (bacterial enzymes) or coelentrizine and oxygen.

10 The substrate luciferin must be supplied to the luciferase enzyme in order for it to luminesce. Thus, a convenient method for providing luciferin is to express not only the luciferase but also the biosynthetic enzymes for the synthesis of the substrate decanal. Oxygen is then the only extrinsic requirement for bioluminescence, in bacteria expressing these proteins from the Lux operon.

15 For example, the *lux* operon obtained from the soil bacterium *Xenorhabdus luminescence* (Frackman *et al.*, 1990, *J. Bact.* 172:5767-5773) may be used as reporter operon, as it confers on transformed *E. coli* the ability to emit photons through the expression of the two subunits of the heterodimeric luciferase and three accessory proteins (Frackman *et al.*, *supra*).

20 Optimal bioluminescence for *E. coli* expressing the *lux* genes of *X. luminescence* is observed at 37°C (Szittner and Meighen 1990, *J. Biol. Chem.* 265:16581-16587; Xi *et al.*, 1991, *J. Bact.* 173:1399-1405), which contrasts the low temperature optima of luciferases from eukaryotic and other prokaryotic luminescent organisms (Campbell, 1988, Chemiluminescence. Principles and
25 Applications in Biology and Medicine (Chichester, England: Ellis Horwood Ltd. and VCH Verlagsgesellschaft mbH)). Thus, the reporter operon may be chosen according to the nature and the requirements of a specific application. For example, the luciferase from *X. luminescence*, therefore, is well-suited for use as a marker for studies in
30 animals.

Luciferase vector constructs can be adapted for use in transforming a variety of host cells, including most bacteria, and many eukaryotic cells. In addition, certain viruses, such as herpes virus and vaccinia virus, can be genetically-engineered to
35 express luciferase. For example, Kovacs and Mettenlieter, 1991, *J. Gen. Virol.* 72:2999-3008, teach the stable expression of the gene encoding firefly luciferase in a

herpes virus. Brasier and Ron, 1992, *Meth. in Enzymol.* 216:386-396, teach the use of luciferase gene constructs in mammalian cells. Luciferase expression from mammalian cells in culture has been studied using CCD imaging both macroscopically
 5 (Israel and Honigman, 1991, *Gene* 104:139-145) and microscopically (Hooper *et al.*, 1990, *J. Biolum. and Chemilum.* 5:123-130).

C. Imaging Of Light-Emitting Biodetectors

Light emitting biodetectors may be imaged in a number of ways.
 10 Guidelines for such imaging, as well as specific examples, are described below.

1. Photodetector Devices

In one embodiment of the present invention where the signal
 15 generated by the biodetector is light, an important aspect will be the selection of a photodetector device with a high enough sensitivity to enable the imaging of faint light. Furthermore, in cases where the biodetector is used in a living subject, the imaging has to be in a reasonable amount of time, preferably less than about thirty (30) minutes, and
 20 to use the signal from such a device to construct an image.

In cases where it is possible to use light-generating moieties which are extremely bright, and/or to detect light-emitting conjugates localized near the surface of the subject or animal being imaged, a pair of "night-vision" goggles or a standard high-sensitivity video camera, such as a Silicon Intensified Tube (SIT) camera (*e.g.*, Hamamatsu
 25 Photonic Systems, Bridgewater, NJ), may be used. More typically, however, a more sensitive method of light detection is required.

At extremely low light levels, such as those encountered in the practice of the present invention, the photon flux per unit area becomes so low that the scene being
 30 imaged no longer appears continuous. Instead, it is represented by individual photons which are both temporally and spatially distinct from one another. Viewed on a monitor, such an image appears as scintillating points of light, each representing a single detected photon.

35 By accumulating these detected photons in a digital image processor over time, an image can be acquired and constructed. Alternatively, the scintillating points can be

enumerated and reported numerically obviating the image reconstruction step thus expediting the analysis. In contrast to conventional cameras where the signal at each image point is assigned an intensity value, in photon counting imaging the amplitude of the signal carries no significance. The objective is to simply detect the presence of a signal (photon) and to count the occurrence of the signal with respect to its position over time.

At least two types of photodetector devices, described below, can detect individual photons and generate a signal which can be analyzed by an image processor.

10 ***Reduced-Noise Photodetection Devices.*** The first class constitutes devices which achieve sensitivity by reducing the background noise in the photon detector, as opposed to amplifying the photon signal. Noise is reduced primarily by cooling the detector array. The devices include charge coupled device (CCD) cameras referred to as
15 "backthinned", cooled CCD cameras. In the more sensitive instruments, the cooling is achieved using, for example, liquid nitrogen, which brings the temperature of the CCD array to approximately -120°C. The "backthinned" refers to an ultra-thin backplate that reduces the path length that a photon follows to be detected, thereby increasing the
20 quantum efficiency. A particularly sensitive backthinned cryogenic CCD camera is the "TECH 512", a series 200 camera available from Photometrics, Ltd. (Tucson, AZ).

Photon Amplification Devices. A second class of sensitive photodetectors includes devices which amplify photons before they hit the detection screen. This class includes CCD cameras with intensifiers, such as microchannel intensifiers. A
25 microchannel intensifier typically contains a metal array of channels perpendicular to and co-extensive with the detection screen of the camera. The microchannel array is placed between the sample, subject, or animal to be imaged, and the camera. Most of the photons entering the channels of the array contact a side of a channel before exiting.
30 A voltage applied across the array results in the release of many electrons from each photon collision. The electrons from such a collision exit their channel of origin in a "shotgun" pattern, and are detected by the camera.

Even greater sensitivity can be achieved by placing intensifying microchannel
35 arrays in series, so that electrons generated in the first stage in turn result in an amplified signal of electrons at the second stage. Increases in sensitivity, however, are

achieved at the expense of spatial resolution, which decreases with each additional stage of amplification.

An exemplary microchannel intensifier-based single-photon detection device
5 suitable for the practice of the invention is the C2400 series, available from Hamamatsu.

Image Processors. Signals generated by photodetector devices which count
photons need to be processed by an image processor in order to construct an image
which can be, for example, displayed on a monitor or printed on a video printer. Such
image processors are typically sold as part of systems which include the sensitive
10 photon-counting cameras described above, and accordingly, are available from the same
sources (*e.g.*, Photometrics, Ltd., and Hamamatsu). Image processors from other
vendors can also be used, but more effort is generally required to achieve a functional
system.

15 The image processors are usually connected to a personal computer, such as an
IBM-compatible PC or an Apple Macintosh (Apple Computer, Cupertino, CA), which
may or may not be included as part of a purchased imaging system. Once the images
are in the form of digital files, they can be manipulated by a variety of image processing
20 programs (such as "ADOBE PHOTOSHOP", Adobe Systems, Adobe Systems,
Mountain View, CA) and printed.

2. Constructing An Image Of Photon Emission

25 In cases where, due to an exceptionally bright light-generating
moiety and/or localization of light-emitting conjugates near the surface of the subject, a
pair of "night-vision" goggles or a high sensitivity video camera was used to obtain an
image, the image is simply viewed or displayed on a video monitor. If desired, the
signal from a video camera can be diverted through an image processor, which can store
30 individual video frames in memory for analysis or printing, and/or can digitize the
images for analysis and printing on a computer.

Alternatively, if a photon counting approach is used, the measurement of photon
emission generates an array of numbers, representing the number of photons detected at
35 each pixel location, in the image processor. These numbers are used to generate an
image, typically by normalizing the photon counts (either to a fixed, pre-selected value,

or to the maximum number detected in any pixel) and converting the normalized number to a brightness (grayscale) or to a color (pseudocolor) that is displayed on a monitor. In a pseudocolor representation, typical color assignments are as follows. Pixels with zero photon counts are assigned black, low counts blue, and increasing counts colors of increasing wavelength, on up to red for the highest photon count values. The location of colors on the monitor represents the distribution of photon emission, and, accordingly, the location of light-emitting conjugates.

In order to provide a frame of reference for the conjugates, a grayscale image of the (still immobilized) subject from which photon emission was measured is typically constructed. Such an image may be constructed, for example, by opening a door to the imaging chamber, or box, in dim room light, and measuring reflected photons (typically for a fraction of the time it takes to measure photon emission). The grayscale image may be constructed either before measuring photon emission, or after.

The image of photon emission is typically superimposed on the grayscale image to produce a composite image of photon emission in relation to the subject.

If it desired to follow the localization and/or the signal from a light-emitting conjugate over time, for example, to record the effects of a treatment on the distribution and/or localization of a selected biocompatible moiety, the measurement of photon emission, or imaging can be repeated at selected time intervals to construct a series of images. The intervals can be as short as picoseconds (in fast gated cameras) or seconds, to days or weeks with integrating cameras.

D. Applications

Specific applications of the biodetectors include the diagnosis of diseases, detection of clinically relevant substances, detection of environmental contaminants, detection of food contaminants. Further, the biodetectors of the invention will find numerous applications in basic research and development.

Diagnosis Of Infectious Disease. The biodetectors may be used for the detection of antigens in body fluids, including blood or urine, or tissues and other fluids. Suitable target antigens include, but not limited to, bacterial pathogens, viral pathogens, fungal pathogens, serum proteins, lymphokines, cytokines, cytotoxins, interferons, β -2

microglobulin, immunoglobulins, peptides, and polypeptides.

- Specific diagnostic tests targeting bacterial pathogens may include, but are not limited to, diagnosis of lyme disease, *Streptococcus*, *Salmonella*,
 5 *Tuberculosis*, *Staphylococcus*, *Pseudomonas*, *Helicobacter*, *Listeria*,
Shigella, *Proteus*, *Enterococci*, *Clostridium*, *Bordatella*,
Bartonella, *Rickettsia*, *Chlamydia*, *Spirochetes*. Diagnostic tests targeting
 viral pathogens may include, but are not limited to, the detection of retroviruses, such
 as HIV-1, HTLV-1, hepatitis viruses (HBV, HCV, HAV), herpes viruses, including
 10 EBV, CMV, *herpes simplex I*, *herpes simplex II*, and HHV-6, encephalitis,
 including Japanese encephalitis virus, Eastern and Western Encephalitis Virus, rotavirus,
 all known and yet to be identified human and animal viral pathogens and unconventional
 agents such as those associated with Alzheimer's and Crutzfeld-Jacob disease (prions).
 15 Targeting fungal pathogens may include, but are not limited to, cryptococcus,
 histoplasmosis, coccidioides, candida, giardia.

- Detection Of Other Clinically Relevant Substances.** Applications of the
 biotectors may include the detection of clinically relevant substances, such as sugar
 20 molecules, fatty acids, proteins or microorganisms, in body fluids, *e.g.*, blood or
 urine, or tissue. Targeted antigens may include enzymes indicating the proper function
 of organs, including lactate dehydrogenase, urea, glucose, and other small molecules,
 and cytokines. Alpha fetal protein may be targeted for the diagnosis of spinobifida.
 25 Certain bacterial species or other microorganisms may be targeted to measure their
 representation in mixed populations such as gut and vaginal flora. An important
 diagnostic target will be lymphokines for the diagnosis and prognosis of a range of
 diseases. With current methods, the profile of lymphokines cannot easily be
 determined, however, it can be expected that its determination will elucidate a wide
 30 array of unknown aspects about the relationship of diseases and disease states. Further,
 an important medical application will be the early, perinatal diagnosis of genetic
 diseases, including cystic fibrosis, sickle cell anemia, Down syndrome, phenylketonuria,
 ADA deficiency, thalassemias, growth hormone deficiency, predisposition of cancer.
 35 Finally, the biotectors may find application in the real time monitoring of, *e.g.*,
 glucose levels and drug levels.

Agricultural And Veterinary Applications. All above described medical applications may be applied to veterinary medicine.

Detection Of Environmental Contaminants. For example, the biotectors may
5 be used for detection of contaminants in water supply. Selected targets may include, but
are not limited to *Giardia*, *Cryptococcus*, *Legionella*, *Clostridia* toxins,
Enterobacter, *E. coli*, protozoans, heavy metals. Further, representation of
certain bacteria in soil populations may be measured by the means of the biotectors;
soil may be screened to track genetically engineered organisms that might have been
10 released into the environment.

Detection Of Food Contaminants. The biotectors may be employed to identify
contaminants in food, including, but not limited to bacteria, such as *salmonella*,
coliforms, *staphylococcus*, *clostridium*, and fungi.

15 **Basic Research And Development.** The biotectors will find numerous
applications in basic research and development. Examples include detection system in
standard immunoassay, such as Western Blots, ELISA, the determination of lymphokine
profiles, the detection of cell culture contamination, including *Mycoplasma*. Further,
20 the biotectors will be useful as detection system in expression assays, for the detection
of cell surface markers, such as CD4, CD8, adhereins.

Abiotic Biotectors. For certain applications, when antigenicity is an issue
(i.e., *in vivo*) abiotic biotectors may be desirable. Examples include the *in*
25 *vivo* detection and localization of infection, tissue damage and other pathologies.
Encapsulation of the biotector mechanism in generally inert vesicles bilayer or
membranes or any other entity that is non-living and will preserve vectoral metabolism
(such as liposomes) in such way that contact with ligands results in light will permit the
use of this system *in vivo*.

30

The below examples explain the invention in more detail. The following
preparations and examples are given to enable those skilled in the art to more clearly
understand and to practice the present invention. The present invention, however, is not
35 limited in scope by the exemplified embodiments, which are intended as illustrations of
single aspects of the invention only, and methods which are functionally equivalent are

within the scope of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

VII. EXAMPLES

The first three examples are three approaches which may be employed to link the signal transduction to the expression of a specific gene.

A. Example 1: Linking Signal Transduction To The Regulation Of A Specific Genes (Approach 1)

The following example illustrates an approach which can be used to link the signal transduction to regulation of a specific gene.

A transposon is constructed to identify promoters that are activated by ligand binding to surface expressed ligand-binding molecules, *e.g.*, antibodies. Promoterless reporter systems have been employed for identifying a variety of regulatory sequences in bacteria. Ronald *et al.*, 1990, *Gene* 90:145-148. The transposon consists of (i) (1) a promoterless operon containing the genes for bioluminescence, (2) a selectable marker (kanamycin resistance gene; Kan), and (3) a negative regulator (the lambda repressor); (ii) an additional selectable marker (chloramphenicol resistance gene; Chl) expressed by the lambda operator; and (iii) a third selectable marker that is constitutively expressed (ampicillin resistance gene; Amp). Bacterial cells expressing the antibody of interest are transformed with the transposon. The conformational change in the transmembrane antibody-fusion protein signals the activation or chemical modification of the transducer which is designed to relay that message to the promoter region of the lux construct. Positive transformants are selected by determination of the acquired Amp resistance. Cells containing the transposon behind promoters that are active in the presence of antigen (including constitutive expression) will be Kan resistant in the presence of antigen, and cells containing a transposon behind promoters that are off in the absence of antigen will be Chl resistant in the absence of antigen. Therefore by passage through a series of growth conditions the desired transformants that appropriately express luciferase in response to

antigens will be identified. The promoters can then be characterized and used to construct additional biodetectors.

FIGURE 4 depicts a biodetector generated as described in EXAMPLE 1. As shown in FIGURE 4A, in the absence of antigen, the fusion protein does not transduce a signal to the promoter which drives expression of the cloned genes encoded by the integrated transposon. Therefore, the phenotype of the proposed *E. coli*, in the absence of antigen, is ampicillin resistant, chloramphenicol resistant, kanamycin sensitive, and not bioluminescent. Ampicillin resistance is constitutively expressed to maintain selection of the integrated transposon.

When, however, the promoter is turned on by binding of the activated transducer, which is activated by ligand binding to the fusion protein, the luciferase operon, the kanamycin resistance gene, and the lambda repressor are expressed. The lambda repressor acts on the lambda operator, thereby shutting down the expression of the chloramphenicol resistance gene. In the presence of antigen the phenotype of the cells is therefore characterized by ampicillin resistance, kanamycin resistance, chloramphenicol sensitivity, and bioluminescence.

Thus, induction and activation of genes as described above permits positive selection for the desired response to antigen. More specifically, only those bacterial cells which integrate the described transposon at a suitable site in the genome survive the selection procedures while nonresponsive bacteria die.

B. Example 2: Linking Signal Transduction To The Regulation Of A Specific Genes (Approach 2)

The following example illustrates an second approach which can be used to link the signal transduction to regulation of a specific gene.

The fusion protein composed of an antibody heavy chain and a surface protein known to transduce signals for gene regulation, and a promoter that is affected by this signal is placed in front of the marker gene. Antibody light chains are coexpressed in the biodetector to provide additional ligand specificity (Borrebaeck *et al.*, 1992, *Biotechnology* 10:697-698). Bacterial phosphatase has been selected as the initial transmembrane and signal-transducing component of the gene fusion because of its current use in identifying surface expressed fusion proteins in bacteria (Kohl *et al.*,

1990, *Nucleic Acids Res.* 18:1069; Weiss and Orfanoudakis, 1994; *J. Biotechnol.* 33:43-53) and a colorimetric substrate is available for measuring phosphatase activity. Antibody fragment-phosphatase fusions have been generated with retention of both ligand binding specificity and phosphatase activity (Kohl *et al.*,
 5 1991, *Acad. Sci.* 646:106-114; Wels *et al.*, 1992, *Biotechnology* 10:1128-1132). Phosphatase-antibody fusions have been used to generate labeled antibodies for immunoassay (Carrier *et al.*, 1995, *J. Immunol. Methods* 181:177-186; Ducancel
 10 *et al.*, 1993, *Biotechnology* 11:601-605; Weiss *et al.*, 1994, *J. Biotechnol.* 33:43-53; Wels *et al.*, 1992, *Biotechnology* 10:1128-1132). In addition, antibodies to modified bacterial phosphatase have been shown to alter phosphatase function (Brennan
 15 *et al.*, 1995, *Proc. Natl. Acad. Sci. U.S.A.* 92:5783-5787), indicating that protein-protein interactions can modulate phosphatase activity most likely through conformational changes in the phosphatase molecule. Expression of phosphatase fusion proteins on bacterial cell surfaces transduces a signal, phosphorylation into the cell which induces expression of specific genes. This system may be modified to tightly link
 20 the expression of the marker proteins, luciferase and its accessory proteins, to binding of the ligand to the antibody-phosphatase fusion protein, *i.e.*, a ligand-dependent molecular switch.

25 C. Example 3: Linking Signal Transduction To The Regulation Of A Specific Genes (Approach 3)

The following example illustrates an third approach which can be used to link the signal transduction to regulation of a specific gene.

The approaches described in EXAMPLE 1 and 2 may be combined using the
 30 transposon described above in cells expressing the phosphatase-antibody fusions.

A bacterial strain is established that has a reporter gene linked to an inducible promoter that responds specifically to the activation of a transducer molecule for example, those of the *pho* operon. An antibody repertoire library cloned into an vector
 35 that will fuse the antibody to a *pho* membrane protein can then be put into the above bacterial strain. This library of biodetectors can then be tested against specific molecules that are of interest to detect and selection of the appropriate biodetector can

be made. This resulting bioreporter can then be propagated in large amounts.

D. Example 4: Detection Of Substances in Solution

The following is an illustrative assay to detect ligands including viral and bacterial antigens in solutions such as whole blood and plasma.

Samples containing the ligand to be detected and quantified are diluted (2 fold serial dilutions) in 96 well plates along with reference standards. The specific bioreporter is added to each of the wells as a viable active cell, and analyzed immediately. Bioluminescent signals from the plate are detected using a charge coupled device (CCD camera) or a luminometer in a 96 well format. Relative bioluminescence from the unknown samples are plotted on a standard curve for quantitation.

E. Example 5: Detection of Substances On Solid Support

The following is an illustrative assay to detect substances on solid supports such as nitrocellulose or nylon membranes, *e.g.*, in Western blot analyses using specific bioreporters.

Following transfer of the proteins to a solid support (PVDF Immobilon membrane, Millipore) using standardized procedures, the membrane is dried and transferred to a dish containing the specific bioreporter, as a biological active cell, in minimal medium or other clear buffer containing nutrients for bacterial metabolism. After 30 minutes incubation at room temperature, the membrane is removed sealed, while still wet, in a zip lock or heat sealable plastic bag. Bioluminescent signal from the bioreporters bound to the membrane is detected using an X-ray film, a CCD detector, or other light sensitive detection methods. Signals can be quantified using standard image analysis software.

F. Example 6: Effect Of Human Blood On The Light Emission From Bioluminescent *Salmonella*

As demonstrated in the following example, fewer than ten (10) bacterial cells can be detected with an intensified CCD detector.

Two fold serial dilutions of *Salmonella*, strain LB5000, that had been transformed with a plasmid that conferred constitutive expression of the luciferase

operon were plated in duplicate into 96 well plates. Dilutions were made in 30 μ l of growth medium alone (indicated as LB5000) and with 30 μ l of blood to determine the effects of blood as a scattering and absorbing medium on the limits of detection. Each dilution and the numbers of colony forming units (CFU) implied from plating samples from concentrated wells are indicated in FIGURE 5. The relative bioluminescence for each well as determined by analysis of the image generated by the CCD detector is shown (FIGURE 5). The signal in the more concentrated wells was off scale and the numbers are therefore not linear at higher concentrations.

All references are incorporated in their entirety.

IT IS CLAIMED:

1. A biodetector for the detection of a selected substance comprising:
 - (a) a signal converting element, comprising an extracellular ligand-specific moiety and an intracellular signal transforming domain, wherein said extracellular
5 ligand-specific moiety selectively recognizes said selected substance, which recognition activates said intracellular signal transforming domain;
 - (b) a transducer, wherein said transducer has an inactive and an active form which are distinct from each other, and wherein said activated intracellular signal
10 transforming domain converts said inactive form of said transducer into said active form of said transducer; and
 - (c) a responsive element, wherein said responsive element is activated by said active form of said transducer, resulting in a detectable signal.
15
2. The biodetector of Claim 1 wherein said responsive element comprises a transcription activation element which is activated by said active form of said
20 transducer.
3. The biodetector of Claim 2 wherein said responsive element further comprises a nucleic acid encoding one or a plurality of gene product, which gene product or gene products produce said detectable signal, and wherein said nucleic acid is
25 operatively linked to said transcription activation element.
4. The biodetector of Claim 3 wherein said detectable signal is light.
5. The biodetector of Claim 3 wherein said gene product is detectable by
30 means selected from the group consisting of bioluminescence, colorimetric reactions or fluorescence.
6. The biodetector of Claim 3 wherein said nucleic acid comprises a
35 luciferase operon.

7. The biodetector of Claim 6 wherein said intracellular signal transforming element is a membrane signal transducer.

5 8. The biodetector of Claim 7 wherein said membrane signal transducer is selected from the group consisting of bacterial two component regulatory systems, eukaryotic receptor-mediated signal transducers, prokaryotic receptor-mediated signal transducers.

10 9. The biodetector of Claim 6 wherein said substance is selected from the group consisting of microorganism, virus, retrovirus, protein, sugar, ion.

10. A method for detection of a selected substance comprising:
15 (a) generating a biodetector comprising:
(i) a signal converting element, comprising an extracellular ligand-specific moiety and an intracellular signal transforming domain, wherein said extracellular ligand-specific moiety selectively recognizes said selected substance, which
20 recognition activates said intracellular signal transforming domain;
(ii) a transducer, wherein said transducer has an inactive and an active form which are distinct, and wherein said inactive form is converted into said active form by said activated intracellular signal transforming domain; and
(iii) a responsive element, wherein said responsive element is activated
25 by said active form of said transducer, resulting in a detectable signal;
(b) adding said biodetector to a sample;
(c) measuring and quantifying said detectable signal; and
(d) correlating the levels of said detectable signal with the presence and quantity
30 of said substance.

11. The method of Claim 10 wherein said responsive element of said biodetector comprises a transcription activation element which is activated by said active
35 form of said transducer.

12. The method of Claim 10 wherein said responsive element further comprises a nucleic acid encoding one or a plurality of gene products which gene product or gene products produce said detectable signal, and wherein said nucleic acid is
5 operatively linked to said transcription activation element.

13. The method of Claim 12 wherein said detectable signal is light.

14. The method of Claim 12 wherein said gene product is detectable by means
10 selected from the group consisting of bioluminescence, colorimetric reactions or fluorescence.

15. The method of Claim 12 wherein said nucleic acid comprises a luciferase
15 operon.

16. The biodetector of Claim 10 wherein said substance is selected from the group consisting of microorganism, virus, retrovirus, protein, sugar, ion.

17. The method of Claim 13 wherein said detectable signal is detected by a
20 light detection system.

18. The method of Claim 17 wherein said light detection system is selected
25 from the group consisting of luminometer, spectrophotometer, fluorimeter, CCD detector.

19. The method of Claim 18 wherein the biodetector or the sample is fixed on a
30 solid support.

20. The method of Claim 19 which further includes fixing a series of
biodetectors in an ordered array on a solid support such that a variety of substances
35 comprised in a sample can be detected.

ABSTRACT

The present invention relates to biodetectors for detecting and quantifying molecules in liquid, gas, or matrices. More specifically, the present invention relates to biodetectors comprising a molecular switching mechanism to express a reporter gene upon interaction with target substances. The invention further relates to methods using such biodetectors for detecting and quantifying selected substances with high specificity and high sensitivity.

10

15

20

25

30

35

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: ☒ Application of: Contag et al.
☐ Patent of:

☒ Serial No.: N/A
☐ Patent No.:

Group Art Unit: Unassigned

☒ Filed: HEREWITH
☐ Issued:

Examiner: Unassigned

For: BIODETECTORS TARGETED TO
SPECIFIC LIGANDS

Attorney Docket No.:
8678-004-999

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
[37 CFR 1.9(f) and 1.27(c)] - Small Business Concern

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act in behalf of
the concern identified below:

Name of concern Xenogen

Address of concern 6110 Bollinger Road

San Jose, CA 95129

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the person employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern and/or there is an obligation under contract or law by the inventor(s) to convey rights to the small business concern with regard to the invention, entitled BIODETECTORS TARGETED TO SPECIFIC LIGANDS by inventor(s) Pamela R. Contag, Christopher H. Contag and David A. Benaron described in

- ☒ the specification filed herewith
☐ application serial no. filed
☐ patent no. issued

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention,

any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28 (b)]


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, and patent issuing thereon, or any patent to which this verified statement is directed.

Send correspondence to: PENNIE & EDMONDS LLP Direct Telephone calls to:
1155 Avenue of the Americas
New York, N.Y. 10036-2711 (212) 790-9090


Name of person signing _____
Title of person other than owner _____
Address of person signing _____

Signature _____ Date _____

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)



Unbound Biodeceptor



Bound Biodeceptor

FIGURE 1




FIGURE 2

2025-07-26 10:00





FIGURE 3

A. In the presence of ligand (Amp^r , Kan^r , Chl^s and bioluminescent).



B. In the absence of ligand (Amp^r , Chl^r , Kan^s and NOT bioluminescent)




FIGURE 4

Effect of Human Blood on Signal from Bioluminescent *Salmonella*




FIGURE 5

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

BIODETECTORS TARGETED TO SPECIFIC LIGANDS

and for which a patent application:

- ☐ is attached hereto and includes amendment(s) filed on _____ (if applicable)
- ☒ was filed in the United States on April 19, 1996 as Application Serial No. 60/015,633 (for declaration not accompanying application)
- with amendment(s) filed on _____ (if applicable)
- ☐ was filed as PCT international application Serial No. _____ on _____ and was amended under PCT Article 19 on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE
60/015,633	April 19, 1996

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), Gerald J. Flintoft (Reg. No. 20823), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Isaac Jarkovsky (Reg. No. 22713), Joseph V. Colaianni (Reg. No. 20019), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Jon R. Stark (Reg. No. 30111), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Albert P. Halluin (Reg. No. 25227), Samuel B. Abrams (Reg. No. 30,605), Steven I. Wallach (Reg. No. 35,402), and Marcia H. Sundeen (Reg. No. 30893), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 2730 Sand Hill Road, Menlo Park, CA 94025, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO: PENNIE & EDMONDS 1155 AVENUE OF THE AMERICAS NEW YORK, N.Y. 10036-2711				DIRECT TELEPHONE CALLS TO: PENNIE & EDMONDS DOCKETING (212) 790-2803	
201	FULL NAME OF INVENTOR	LAST NAME CONTAG	FIRST NAME PAMELA	MIDDLE NAME R.	
	RESIDENCE & CITIZENSHIP	CITY SAN JOSE	STATE OR FOREIGN COUNTRY CALIFORNIA	COUNTRY OF CITIZENSHIP US	
	POST OFFICE ADDRESS	STREET 6110 BOLLINGER ROAD	CITY SAN JOSE	STATE OR COUNTRY CALIFORNIA	ZIP CODE 95129
202	FULL NAME OF INVENTOR	LAST NAME BENARON	FIRST NAME DAVID	MIDDLE NAME A.	
	RESIDENCE & CITIZENSHIP	CITY REDWOOD CITY	STATE OR FOREIGN COUNTRY CALIFORNIA	COUNTRY OF CITIZENSHIP US	
	POST OFFICE ADDRESS	STREET 454 BIRCH STREET	CITY REDWOOD CITY	STATE OR COUNTRY CALIFORNIA	ZIP CODE 94062
203	FULL NAME OF INVENTOR	LAST NAME CONTAG	FIRST NAME CHRISTOPHER	MIDDLE NAME H.	
	RESIDENCE & CITIZENSHIP	CITY SAN JOSE	STATE OR FOREIGN COUNTRY CALIFORNIA	COUNTRY OF CITIZENSHIP US	
	POST OFFICE ADDRESS	STREET 6110 BOLLINGER ROAD	CITY SAN JOSE	STATE OR COUNTRY CALIFORNIA	ZIP CODE 95129
204	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
205	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
206	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201 - PAMELA R. CONTAG	SIGNATURE OF INVENTOR 202 - CHRISTOPHER H. CONTAG	SIGNATURE OF INVENTOR 203 - DAVID A. BENARON
DATE	DATE	DATE
SIGNATURE OF INVENTOR 204	SIGNATURE OF INVENTOR 205	SIGNATURE OF INVENTOR 206
DATE	DATE	DATE